Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia

Movement Disorders

Volumn 19, Issue 9, 2004, Pages 1075-1079

  Adler, Charles H ^a   Bansberg, Stephen F ^a   Krein Jones, Kari ^a   Hentz, Joseph G ^a  

^a MAYO CLINIC   (United States)

Author keywords

Botulinum toxin type B; Dystonia; Spasmodic dysphonia

Indexed keywords

BOTULINUM TOXIN B;

ADULT; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSPHONIA; DYSPNEA; FEMALE; HUMAN; MALE; MUSCLE SPASM; PRIORITY JOURNAL; RATING SCALE; SORE THROAT; SOUND INTENSITY; TREATMENT OUTCOME; VIDEOTAPE; VOCAL CORD; VOICE;

ADULT; BOTULINUM TOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; SEVERITY OF ILLNESS INDEX; VOCAL CORDS; VOICE DISORDERS;

EID: 4644330948     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20098     Document Type: Article

References (11)

1. Ludlow CL, Rhew K, Nash EA. Botulinum toxin injection for adductor spasmodic dysphonia. In: Jankovic J, Hallet M, editors. Therapy with botulinum toxin. New York: Marcel Dekker; 1994. p 437-450.
2. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 1998;108:1435-1441.
3. Brin MF, Blitzer A, Stewart C. Laryngeal dystonia (spasmodic dysphonia): observations of 901 patients and treatment with botulinum toxin. Adv Neurol 1998;78:237-252.
4. Smith ME, Ford CN. Resistance to botulinum toxin injections for spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 2000; 126:533-535.
5. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999;53:1431-1438.
6. Lew MF, Brashear A, Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology 2000;55(Suppl.):29-35.
7. Aronson AE, et al. Botulinum toxin injection for adductor spastic dysphonia: patient self-ratings of voice and phonatory effort after three successive injections. Laryngoscope 1993;103:683-692.
8. Adler CH. Botulinum toxin treatment of movement disorders. In: Gilman S, Goldstein GW, Waxman SG, editors. Neurobase. San Diego: Arbor Publishing; 1999.
9. Ludlow CL, et al. A comparison of injection techniques using botulinum toxin injection for treatment of the spasmodic dysphonias. J Voice 1992;6:380-386.
10. Whurr R, et al. The use of botulinum toxin in the treatment of adductor spasmodic dysphonia. J Neurol Neurosurg Psychiatry 1993;56:526-530.
11. Zwirner P, Murry T, Woodson GE. A comparison of bilateral and unilateral botulinum toxin treatments for spasmodic dysphonia. Eur Arch Otorhinolaryngol 1993;250:271-276.